AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04532606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
Study NCT04769388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT04769388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT04769388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT06227104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Convection-based Hemodiafiltration
Description: Convection-based Hemodiafiltration with pre substitution fluid
Study NCT06020989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib+Pemetrexed+Carboplatin
Description: Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
Study NCT06020989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
Study NCT05824195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread products
Description: Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
Study NCT05824195 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bread products
Description: Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
Study NCT05381857 — intervention group
Intervention type: OTHER
Intervention: Human Biological Samples
Description: Blood, urine, nasal swab, fecal samples
Study NCT04759326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hippotherapy
Description: Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.
Study NCT04759326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Neurorehabilitation
Description: The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.
Study NCT05961007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of IBI302(dose 1)
Description: IBI302(dose 1) intravitreal injection given as protocol
Study NCT05961007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of IBI302(dose 2)
Description: IBI302(dose 2) intravitreal injection given as protocol
Study NCT05961007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of IBI302(dose 3)
Description: IBI302(dose 3) intravitreal injection given as protocol
Study NCT05961007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of Aflibercept
Description: Aflibercept intravitreal injection given as protocol
Study NCT05063448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DadSpace
Description: A group educational support and mentoring program for perinatal fathers.
Study NCT05292157 — intervention group
Intervention type: PROCEDURE
Intervention: shoulder arthroplasty
Description: range of motion (in degrees) measured in annual postoperative follow-up
Study NCT05178797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping technique with exercise therapy
Description: Kinesiology tape is a latex-free fiber that stretches longitudinally \& elastic with an acrylic adhesive. It is used to stimulate dermal mechanoreceptors, encourages sensory and mechanical stimuli resulting in reduction of clogging lymphatic flow which limits the circumference of the affected limb in the region where it is applied due to its flexibility and acts over the lymphatic system. However, exercise therapy is systematic movement program to strengthen muscles.
Study NCT05178797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression decongestive therapy
Description: It consists of two phases: First is the intensive phase (volume reduction phase), in this phase short stretch bandage, manual lymphatic drainage, skincare and exercises will be given for a period of 4 weeks.~In the second phase (maintenance phase), compression garments and exercises will be given to the patient for maintaining the limb volume or to reduce the risk of lymphedma.
Study NCT06120790 — intervention group
Intervention type: OTHER
Intervention: 3 Oz water screen
Description: Patient will consume 3 oz of water continuously without stopping and then will be monitored for one minute post completion. Patient will complete this twice in the same session.
Study NCT06237478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group L.
Study NCT06237478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group H.
Study NCT05611333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-Led Remote Exercise Program Intervention
Description: The physician-led remote exercise program intervention consists of three 45-minute walking classes on Zoom per week for 4 weeks.
Study NCT05420259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise and Dietary Intervention (CEDI)
Description: The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
Study NCT05420259 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard Care
Study NCT05828485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
Study NCT04786535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded Hemodialysis
Description: * Single-use Theranova 400 Dialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight
Study NCT04786535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flux Conventional Hemodialysis
Description: * Single-use high-flux hemodialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight
Study NCT04786535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: * Single-use high-flux hemodialyzer~* Post-dilution mode~* Minimum convective volume of 23 L~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 700 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight
Study NCT06385782 — intervention group
Intervention type: OTHER
Intervention: Antarctic environment
Description: . According to the different work content of the scientific expedition team members, and taking the average outdoor working time of 2 hours/day as the node, the scientific expedition team members are divided into outdoor groups (n=12) and indoor groups (n=10). Participants will be assessed on the day they enter the Antarctic station and leave.
Study NCT05363306 — intervention group
Intervention type: PROCEDURE
Intervention: implant insertion
Description: 4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component.
Study NCT05593562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Oral 100 mg \[14 c\] SPH3127 mixed suspension
Study NCT04338776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift
Description: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Study NCT04338776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum
Description: The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra.
Study NCT05036421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 milligram
Description: antihyperglycemic medication
Study NCT05373914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cudetaxestat (BLD-0409)
Description: Cudetaxestat - 250mg tablets (orally)
Study NCT05373914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control: Matching Placebo
Description: Placebo - 250mg tablets (orally)
Study NCT05373914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Matching Placebo
Description: Placebo - 250mg tablets (orally)
Study NCT06335563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AR glasses-assisted pulmonary nodule puncture localization
Description: Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
Study NCT06335563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided pulmonary nodule puncture localization
Description: Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
Study NCT05219370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: administration of different cannabis oil types as compared with placebo
Study NCT05219370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis oil
Description: administration of different cannabis oil types as compared with placebo
Study NCT04549298 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study NCT05335278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 milligrams [Ofev]
Description: All patients will be given nintedanib 150 milligrams orally twice daily
Study NCT04444440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Fluoroquinolone antibiotic.
Study NCT04444440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo Pill
Study NCT05647603 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: Information about contraception
Study NCT04754659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stentgraft
Description: Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.
Study NCT04754659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stentgraft
Description: Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.
Study NCT04860778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BDNF Essentials
Description: Participants will take two capsules, twice daily with water for 84 days.
Study NCT05217316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Virtual Toothbrushing
Description: A supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child. All virtual appointments will be conducted using the collaboration of two national platforms. Mawid, a Ministry of health (MOH) Central Appointment System, to be used by the subjects. And ANAT system, a Saudi Commission for Health Specialists (SCHS) application for the hygienists to use for their virtual supervision.
Study NCT05306756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Blood Sampling (FBS)
Description: Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
Study NCT05306756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: digital Fetal Scalp Stimulation (dFSS)
Description: Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
Study NCT06213103 — intervention group
Intervention type: PROCEDURE
Intervention: Patient cohort
Description: Collection of 6 blood tubes at the inclusion visit.
Study NCT06213103 — intervention group
Intervention type: PROCEDURE
Intervention: Control cohort
Description: Collection of 6 blood tubes at the inclusion visit.
Study NCT05636449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Suprainguinal fascia iliaca block
Description: After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
Study NCT05636449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Periarticular Infiltration
Description: A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
Study NCT04976907 — intervention group
Intervention type: DEVICE
Intervention: Contactless vital sign information collection
Description: Collection of facial blood flow and temperature information via conventional and infrared/thermal video of the face for the purpose of estimating vital signs using machine learning-based computational models.
Study NCT06048640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dynamine (methylliberine)
Description: Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
Study NCT06048640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dynamine (methylliberine)
Description: Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
Study NCT04768608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1-PSMA-CART cells
Description: PD1-PSMA-CART cells will be given IV at split doses
Study NCT04600661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise therapy
Description: Neuromuscular training
Study NCT05435443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PowerBreathe and PEP Therosold tools
Description: Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM.